Trial Profile
VOLTAIRE-X: Pharmacokinetics, Safety, Immunogenicity and Efficacy of BI 695501 Versus Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis: a Randomized, Double-blind, Parallel-arm, Multiple-dose, Active Comparator Trial
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Plaque psoriasis
- Focus Pharmacokinetics; Registrational
- Acronyms VOLTAIRE-X
- Sponsors Boehringer Ingelheim
- 15 Nov 2023 Results of pooled subgroup analysis from five phase 3 randomized controlled clinical trials (VOLTAIRE-RA , VOLTAIRE-RAext, VOLTAIRE-CD, VOLTAIRE-PsO and VOLTAIRE-X) assessing incidence of safety endpoints in patients with RA )presented at the ACR Convergence 2023
- 24 Oct 2023 Results published in the Dermatology and Therapy.
- 01 Jul 2023 According to a Boehringer Ingelheim media release, the company announced today that Cyltezo (adalimumab-adbm), a U.S. Food and Drug Administration (FDA)-approved Interchangeable biosimilar to Humira (adalimumab), is now commercially available in the U.S. Cyltezo was initially approved as a biosimilar in 2017 for use in multiple chronic inflammatory diseases.